Submissions from 2022
Concurrent p53 mutation in EGFR mutant non-small cell lung cancer is associated with resistance to first and second generation EGFR tyrosine kinase inhibitors, a meta-analysis, Marissa Viola, Adam Kolatorowicz, and Jun Wang
Concurrent p53 mutation in EGFR mutant non-small cell lung cancer is associated with resistance to first and second generation EGFR tyrosine kinase inhibitors, a meta-analysis, Marissa Viola, Adam Kolatorowicz, and Jun Wang
